Figure 3.

Representation of echocardiographic images (parasternal long-axis view) at different levels of wall thickness in transthyretin amyloid cardiomyopathy. The ideal therapeutic window would be to identify these patients at the earliest stage possible with near normal or mildly increased wall thickness before decline in quality of life, elevation in cardiac biomarkers, and overt cardiac manifestations of disease.¹⁵ NAC: National Amyloidosis Center; MRI: magnetic resonance imaging; Echo: echocardiography; EKG: electrocardiogram; NTproBNP: N-terminal-pro hormone brain natriuretic peptide; TTR: transthyretin